Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.55 |
| ▸ | CNR2 | P34972 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24437306 | 0.96 | CNR1 (0.52) | CNR1CNR2ALDH1A1P2RX7CYP1A2 | |
| SCHEMBL24437378 | 0.93 | CNR1 (0.60) | CNR1CNR2ALDH1A1P2RX7SMN1; SMN2 | |
| SCHEMBL24437303 | 0.88 | CNR1 (0.56) | CNR1CNR2ALDH1A1P2RX7CYP1A2 | |
| SCHEMBL24437138 | 0.84 | CNR1 (0.57) | CNR1CNR2ALDH1A1P2RX7 | |
| SCHEMBL29735513 | 0.80 | NPC1 (0.59) | ALDH1A1P2RX7SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL19127904 | 0.80 | NPC1 (0.59) | ALDH1A1P2RX7SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL24437316 | 0.79 | CNR1 (0.53) | CNR1CNR2ALDH1A1P2RX7 | |
| SCHEMBL19127229 | 0.79 | HTT (0.54) | ALDH1A1SMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29735646 | 0.79 | HTT (0.54) | ALDH1A1SMN1; SMN2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL24437144 | 0.77 | CNR1 (0.54) | CNR1CNR2ALDH1A1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153735-A1 | Orai Channel Inhibitors | ORAI2, ORAI1, ORAI3 | CNR1 940/4885CNR2 745/4885ALDH1A1 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.